561 related articles for article (PubMed ID: 33309579)
1. Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients.
Srivastava PK; DeVore AD; Hellkamp AS; Thomas L; Albert NM; Butler J; Patterson JH; Spertus JA; Williams FB; Duffy CI; Hernandez AF; Fonarow GC
JACC Heart Fail; 2021 Jan; 9(1):28-38. PubMed ID: 33309579
[TBL] [Abstract][Full Text] [Related]
2. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS
Eur J Heart Fail; 2021 Sep; 23(9):1499-1511. PubMed ID: 34132001
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971
[TBL] [Abstract][Full Text] [Related]
4. Reduction of heart failure guideline-directed medication during hospitalization: prevalence, risk factors, and outcomes.
Palin V; Drozd M; Garland E; Malik A; Straw S; McGinlay M; Simms A; Gatenby VK; Sengupta A; Levelt E; Witte KK; Kearney MT; Cubbon RM
ESC Heart Fail; 2022 Oct; 9(5):3298-3307. PubMed ID: 35796239
[TBL] [Abstract][Full Text] [Related]
5. Effect of Optimizing Guideline-Directed Medical Therapy Before Discharge on Mortality and Heart Failure Readmission in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
Yamaguchi T; Kitai T; Miyamoto T; Kagiyama N; Okumura T; Kida K; Oishi S; Akiyama E; Suzuki S; Yamamoto M; Yamaguchi J; Iwai T; Hijikata S; Masuda R; Miyazaki R; Hara N; Nagata Y; Nozato T; Matsue Y
Am J Cardiol; 2018 Apr; 121(8):969-974. PubMed ID: 29477488
[TBL] [Abstract][Full Text] [Related]
6. Mortality and guideline-directed medical therapy in real-world heart failure patients with reduced ejection fraction.
McCullough PA; Mehta HS; Barker CM; Van Houten J; Mollenkopf S; Gunnarsson C; Ryan M; Cork DP
Clin Cardiol; 2021 Sep; 44(9):1192-1198. PubMed ID: 34342033
[TBL] [Abstract][Full Text] [Related]
7. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.
Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M
Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210
[TBL] [Abstract][Full Text] [Related]
8. Association between a hospitalization for heart failure and the initiation/discontinuation of guideline-recommended treatments: An analysis from the Swedish Heart Failure Registry.
Schrage B; Lund LH; Benson L; Braunschweig F; Ferreira JP; Dahlström U; Metra M; Rosano GMC; Savarese G
Eur J Heart Fail; 2023 Jul; 25(7):1132-1144. PubMed ID: 37317585
[TBL] [Abstract][Full Text] [Related]
9. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC
J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570
[TBL] [Abstract][Full Text] [Related]
10. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
Malgie J; Clephas PRD; Brunner-La Rocca HP; de Boer RA; Brugts JJ
Heart Fail Rev; 2023 Sep; 28(5):1221-1234. PubMed ID: 37311917
[TBL] [Abstract][Full Text] [Related]
11. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
[TBL] [Abstract][Full Text] [Related]
12. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
[TBL] [Abstract][Full Text] [Related]
13. Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction.
Lee YC; Lin JK; Ko D; Cheng S; Patorno E; Glynn RJ; Tsacogianis T; Kim DH
J Am Geriatr Soc; 2023 Oct; 71(10):3110-3121. PubMed ID: 37345734
[TBL] [Abstract][Full Text] [Related]
14. Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction.
Sumarsono A; Xie L; Keshvani N; Zhang C; Patel L; Alonso WW; Thibodeau JT; Fonarow GC; Van Spall HGC; Messiah SE; Pandey A
Circulation; 2024 Feb; 149(7):510-520. PubMed ID: 38258605
[TBL] [Abstract][Full Text] [Related]
15. Treatment Patterns, Outcomes, and Persistence to Newly Started Heart Failure Medications in Patients with Worsening Heart Failure: A Cohort Study from the United States and Germany.
Michel A; Lecomte C; Ohlmeier C; Raad H; Basedow F; Haeckl D; Beier D; Evers T
Am J Cardiovasc Drugs; 2024 May; 24(3):409-418. PubMed ID: 38573461
[TBL] [Abstract][Full Text] [Related]
16. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
Peri-Okonny PA; Mi X; Khariton Y; Patel KK; Thomas L; Fonarow GC; Sharma PP; Duffy CI; Albert NM; Butler J; Hernandez AF; McCague K; Williams FB; DeVore AD; Patterson JH; Spertus JA
JACC Heart Fail; 2019 Apr; 7(4):350-358. PubMed ID: 30738978
[TBL] [Abstract][Full Text] [Related]
17. Impact of Pharmacist-Led Heart Failure Clinic on Optimization of Guideline-Directed Medical Therapy (PHARM-HF).
Patil T; Ali S; Kaur A; Akridge M; Eppes D; Paarlberg J; Parashar A; Jarmukli N
J Cardiovasc Transl Res; 2022 Dec; 15(6):1424-1435. PubMed ID: 35501544
[TBL] [Abstract][Full Text] [Related]
18. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction.
Greene SJ; Fonarow GC; DeVore AD; Sharma PP; Vaduganathan M; Albert NM; Duffy CI; Hill CL; McCague K; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Butler J
J Am Coll Cardiol; 2019 May; 73(19):2365-2383. PubMed ID: 30844480
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Guideline-Directed Medical Therapy in Heart Failure Patients With and Without Chronic Kidney Disease: A Meta-Analysis of 63,677 Patients.
Clark KM; Mahboob F; Evans J; Sun JH; Wang N
Heart Lung Circ; 2024 Mar; 33(3):281-291. PubMed ID: 38365495
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice.
Smith KV; Dunning JR; Fischer CM; MacLean TE; Bosque-Hamilton JW; Fera LE; Grant JY; Zelle DJ; Matta L; Gaziano TA; MacRae CA; Scirica BM; Desai AS
J Pharm Pract; 2022 Oct; 35(5):747-751. PubMed ID: 33813934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
